Smith & Nephew plc (NYSE:SNN) Shares Sold by Clean Yield Group

Clean Yield Group cut its stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 80.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,846 shares of the medical equipment provider's stock after selling 150,568 shares during the quarter. Clean Yield Group's holdings in Smith & Nephew were worth $1,017,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of SNN. PNC Financial Services Group Inc. boosted its position in shares of Smith & Nephew by 4.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock valued at $224,000 after buying an additional 399 shares during the last quarter. National Bank of Canada FI lifted its stake in Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 446 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in Smith & Nephew by 3.5% during the fourth quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider's stock valued at $435,000 after purchasing an additional 596 shares during the period. Signaturefd LLC lifted its position in shares of Smith & Nephew by 4.3% during the 4th quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock valued at $388,000 after buying an additional 653 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares during the period. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew Price Performance

Shares of SNN stock traded up $0.08 during trading hours on Wednesday, hitting $30.14. The stock had a trading volume of 637,845 shares, compared to its average volume of 794,551. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew plc has a one year low of $23.69 and a one year high of $31.72. The stock's 50-day moving average price is $27.70 and its two-hundred day moving average price is $26.75. The stock has a market capitalization of $13.20 billion, a price-to-earnings ratio of 13.95, a PEG ratio of 1.26 and a beta of 0.68.

Analysts Set New Price Targets

Several analysts have recently issued reports on SNN shares. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. HSBC cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Canaccord Genuity Group upped their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res cut shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Wall Street Zen raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Smith & Nephew currently has an average rating of "Hold" and an average price target of $28.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.